Cargando…

A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients.

Twelve premenopausal patients with advanced breast cancer were randomised to receive 3.75 or 7.5 mg of a slow release formulation of the luteinising hormone releasing hormone agonist leuprorelin once every 4 weeks. All patients were oestrogen receptor positive or unknown. Serum levels of gonadotroph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dowsett, M., Mehta, A., Mansi, J., Smith, I. E.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1990
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971512/ https://www.ncbi.nlm.nih.gov/pubmed/2123115

Ejemplares similares

Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects.
por: Crighton, I. L., et al.
Publicado: (1989)

The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
por: Stein, R. C., et al.
Publicado: (1990)

Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial
por: Ohashi, Yasuo, et al.
Publicado: (2017)

Clinical Studies Investigating the Use of Leuprorelin in Breast Cancer Patients from Asia
por: Han, Wonshik, et al.
Publicado: (2019)

Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
por: Harris, A. L., et al.
Publicado: (1983)

Adjuvant endocrine therapy for premenopausal women with early breast cancer
por: Bao, Ting, et al.
Publicado: (2007)

A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer
por: Shiba, Eiichi, et al.
Publicado: (2015)

Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
por: Dowsett, M., et al.
Publicado: (1984)

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer
por: Forward, D P, et al.
Publicado: (2004)

Diffuse Leukoplakia of the Bladder Ostium-Sparing in Patient Treated with Leuprorelin for Breast Cancer
por: Nacchia, Antonio, et al.
Publicado: (2021)

Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women
por: Pritchard, Kathleen
Publicado: (2005)

Clinical studies investigating the use of leuprorelin for prostate cancer in Asia
por: Chung, Byung Ha, et al.
Publicado: (2020)

High dose ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer.
por: Harris, A. L., et al.
Publicado: (1988)

Leuprorelin depot injection: patient considerations in the management of prostatic cancer
por: Abouelfadel, Zinelabidine, et al.
Publicado: (2008)

A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1985)

A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer
por: Kurebayashi, Junichi, et al.
Publicado: (2021)

Interstitial pneumonitis secondary to leuprorelin acetate for prostate cancer
por: Tan, Hsern Ern, et al.
Publicado: (2016)

Is High-Dose Leuprorelin Acetate Effective and Safe in Asian Men with Prostate Cancer? An Open-Label, Non-Comparative, Multi-Center Clinical Trial
por: Lee, Seung-Hwan, et al.
Publicado: (2014)

Polymorphisms, endogenous hormone levels and familial breast cancer risk in premenopausal women
por: Walker, K, et al.
Publicado: (2010)

Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease
por: Goldhirsch, Aron, et al.
Publicado: (2015)

Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico
por: Villarreal-Garza, Cynthia, et al.
Publicado: (2021)

Foreign Body Granuloma Secondary to Leuprorelin Acetate
por: Lee, Bo In, et al.
Publicado: (2014)

Inclusion of premenopausal women in breast cancer clinical trials
por: Corrigan, Kelsey L., et al.
Publicado: (2022)

Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?
por: Lambertini, Matteo, et al.
Publicado: (2018)

An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project
por: Pelizzari, Giacomo, et al.
Publicado: (2018)

Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study
por: Kurebayashi, Junichi, et al.
Publicado: (2016)

A Case of Paraphilia with Osteoporosis and Administered with Depot Leuprorelin
por: Kim, Dohee, et al.
Publicado: (2019)

Family history and survival in premenopausal breast cancer.
por: Mohammed, S. N., et al.
Publicado: (1998)

Health belief about adjuvant endocrine therapy in premenopausal breast cancer survivors: a qualitative study
por: Xu, Lei, et al.
Publicado: (2019)

Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
por: Sethi, Rajni, et al.
Publicado: (2009)

Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
por: Tunn, Ulf W, et al.
Publicado: (2013)

A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey.
por: Thomas, H. V., et al.
Publicado: (1997)

Comparison of changes in lipid profiles of premenopausal women with early-stage breast cancer treated with different endocrine therapies
por: Wang, Kaiyue, et al.
Publicado: (2022)

Foreign Body Granulomas Induced by Intramuscular Leuprorelin Acetate Injection for Prostate Cancer: Clinical Mimics of Soft Tissue Sarcoma
por: Thway, Khin, et al.
Publicado: (2015)

A Case of Mental Retardation with Paraphilia Treated with Depot Leuprorelin
por: Park, Woo Sung, et al.
Publicado: (2014)

Therapeutic Effects of Leuprorelin (Leuprolide Acetate) in Sexual Offenders with Paraphilia
por: Choi, Jong Hyuk, et al.
Publicado: (2018)

Leuprorelin/tamoxifen: Impairment of ventricular repolarisation reserve: case report
Publicado: (2021)

Development of Self-Administered Formulation to Improve the Bioavailability of Leuprorelin Acetate
por: Okada, Akie, et al.
Publicado: (2022)

The molecular landscape of premenopausal breast cancer
por: Liao, Serena, et al.
Publicado: (2015)

Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer: A case report
por: Maltoni, Roberta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v15nt3n80p36qjobvh1dmt21js